Form 4: ADC Therapeutics Director Ron Squarer Receives Annual Equity Grant

ADC Therapeutics SA Director Ron Squarer was granted 40,000 Restricted Stock Units as part of his annual compensation, increasing his direct beneficial ownership to 108,811 common shares.

Summary

• Ron Squarer, a Director of ADC Therapeutics SA (ADCT), acquired 40,000 common shares on June 3, 2025.
• This acquisition was an annual grant of Restricted Stock Units (RSUs) made under the Issuer's 2019 Equity Incentive Plan for his service as a Director.
• The RSUs were granted at a price of $0, indicating they are a form of equity compensation.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Mr. Squarer's direct beneficial ownership of ADC Therapeutics common shares increased to 108,811.

Sentiment

Score: 6

Explanation: The document reports a routine annual equity grant to a director, which is a standard compensation practice and aligns management interests with shareholders. It contains no negative surprises or significant new information beyond the compensation event itself.

Positives

• The grant of 40,000 Restricted Stock Units to Director Ron Squarer aligns his interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The transaction reflects ongoing compensation for director service, indicating stability in corporate governance and continued commitment from the director.

Future Outlook

The 40,000 Restricted Stock Units granted to Director Ron Squarer are scheduled to vest one year from the grant date (June 3, 2025), contingent upon his continued service to ADC Therapeutics SA.

Industry Context

This Form 4 filing is a standard disclosure of insider equity transactions, common across publicly traded companies, particularly for director compensation. It does not provide broader industry trends or competitive insights.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns management's financial interests with shareholder value, as the RSUs vest based on continued service and their value is tied to the company's stock performance.

Next Steps

• Vesting of the 40,000 Restricted Stock Units on June 3, 2026, subject to Ron Squarer's continued service as a Director.

Key Dates

Keywords

ADC Therapeutics, ADCT, Ron Squarer, Form 4, SEC filing, Restricted Stock Units, RSU grant, equity compensation, director compensation, beneficial ownership